Last Updated : September 21, 2012
Details
FilesGeneric Name:
Ivacaftor
Project Status:
Complete
Therapeutic Area:
Cystic fibrosis, G551D mutation
Manufacturer:
Vertex Pharmaceuticals Inc.
Call for patient/clinician input open:
Brand Name:
Kalydeco
Project Line:
Reimbursement Review
Project Number:
SR0291-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Cystic Fibrosis patients (G551D mutation)
Recommendation Type:
List with criteria/condition
Final Recommendation:
Files
Last Updated : September 21, 2012